A Phase 3 interventional study of Ibuprofen/acetaminophen and Ibuprofen/acetaminophen (higher dose) in Post-operative Pain, sponsored by Reckitt Benckiser LLC. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-09-17.
Sponsored by Reckitt Benckiser LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing ibuprofen in Pain, Postoperative — 7 open to participants now, 8 under way, none of them phase 3. Ibuprofen · Pain, Postoperative.
Among the 56 studies testing ibuprofen in Pain, Postoperative, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 7 in phase 3, and was the 4th registered.
5,662 studies on the registry are indexed under Pain, Postoperative; 1,238 are open to participants now.
Browse Pain, Postoperative studies →7 of the 56 studies testing ibuprofen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:
University of Puerto Rico · Sites in Puerto Rico
Ages 21–65
University of Michigan · Sites in United States
Ages 12–20
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+ · Women only · Healthy volunteers
Ataturk University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Marquette University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 8 · Phase 4 24
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 678 is above the median of 75 across 4,841 interventional studies indexed under Pain, Postoperative.
Median enrollment 100 across the 56 interventional studies. Of the 39 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under Reckitt Benckiser LLC, one of the names counted as Reckitt. Under that name alone:
Reckitt Benckiser LLC is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Reckitt has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
3 of the studies testing ibuprofen in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07571252University of Puerto RicoImpact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery | 2026-12 |
| NCT05919745Marquette UniversityPreemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft | 2026-12 |
| NCT06495632Cape Fear Valley Health SystemScheduled or as Needed Pain Regimen? | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies testing ibuprofen in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective is to assess the efficacy and tolerability of a combination of 400 mg ibuprofen plus 1000 mg acetaminophen, 200 mg ibuprofen plus 500 mg acetaminophen compared with Nurofen Plus® and Panadeine® Extra.
RB has developed a fixed-dose combination of ibuprofen and acetaminophen (paracetamol). Since the pharmacological actions of ibuprofen and acetaminophen (paracetamol) differ in their site and mode of action, the combination would be expected to be more effective than either active alone, given that pain is multi-factorial with different mediators.
The purpose of this study was to compare the efficacy and tolerability of ibuprofen/acetaminophen (paracetamol) combination with leading market analgesics.
The efficacy and tolerability was assessed in terms of total analgesic effect, peak analgesic effect, onset and duration of action and the subject's overall assessment of the study medication.
Main Inclusion Criteria:
Experiencing moderate to severe pain after extraction of impacted third molars
Main Exclusion Criteria:
Any ongoing painful condition other than that associated with the current third molar surgery that could significantly interfere with the subject's suitability Any condition that would render the subject unsuitable to receive an NSAID, acetaminophen or codeine
One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
Drug: Ibuprofen/acetaminophen
Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
Drug: Ibuprofen/acetaminophen (higher dose)
Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
Drug: Nurofen Plus®
Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
Drug: Panadeine® Extra
Two placebo tablets
Drug: Placebo
Drug pages: Ibuprofen · Acetaminophen
One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
Also known as: Ibuprofen/paracetamol (lower dose)
Drug pages: Ibuprofen · Acetaminophen
Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
Also known as: Ibuprofen/Paracetamol
Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
Also known as: Ibuprofen/Codeine
Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
Also known as: Acetaminophen/codeine, Paracetamol/codeine
Two placebo tablets, single dose taken orally with 300 ml water
Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID)
SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'
Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Change From Baseline in AUC (0-8h) of SPRID
SPRID 0-8h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0 mm = No pain and 100 mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'
Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dose
Change From Baseline in AUC for Pain Intensity Difference Scores (SPID)
Sum of Pain Intensity Difference (SPID) was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Score range: 0mm = No pain and 100mm = Worst pain. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?'
Time frame: 0-4, 0-6, 0-8 and 0-12 hours
Change From Baseline in AUC of Pain Relief Scores (TOTPAR)
Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.
Time frame: 0-4, 0-6, 0-8 and 0-12 hours
Change From Baseline in AUC of Individual Reading Pain Intensity and Relief Scores (SPRID)
SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'
Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours
Individual Pain Intensity Differences (Ordinal)
Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.
Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours
Individual Pain Intensity Differences Visual Analogue Scale (VAS)
Pain Intensity (PI) VAS was measured using a horizontal 100-mm VAS ranging 0 mm = 'No Pain' as the left anchor and 100 mm = 'Worst Pain' as the right anchor, labelled by the subject marking the VAS line in the pain assessment questionnaire in response to the instruction 'Please indicate with a line on the scale below your pain at this time.'
Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours
Change From Baseline in Peak Pain Intensity Difference (Peak PID - Ordinal)
Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.
Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Change From Baseline in Peak Pain Relief (PR)
Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.
Time frame: 0 (baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours post-dose
Subjects' Overall Assessment of the Study Medication Assessed at 12 Hours or Just Before Administration of Rescue Medication
Subject's Overall Assessment measured by subject ticking the appropriate box in response to the question 'How effective do you think the study medication is as a treatment for pain?' Subject's Overall Assessment rated on a five-point ordinal scale: 1 = Poor, 2 = Fair, 3 = Good, 4 = Very good, and 5 = Excellent.
Time frame: At 12 hours
Subjects were recruited in three centres, Salt Lake City (243 subjects randomised), San Marcos (229 subjects randomised) and Austin (206 subjects randomised)
| Milestone | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| Started | 173 | 168 | 169 | 113 | 55 |
| Completed | 172 | 164 | 167 | 112 | 54 |
| Not completed | 1 | 4 | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 |
SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'
| units on a scale*hour | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID) | 2.68 ± 1.59 | 3.30 ± 1.67 | 2.62 ± 1.73 | 1.93 ± 1.51 | 0.54 ± 1.37 |
SPRID 0-8h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0 mm = No pain and 100 mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'
| units on a scale*hour | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| 0-4h | 3.65 ± 1.60 | 3.95 ± 1.52 | 3.44 ± 1.72 | 3.19 ± 1.61 | 0.61 ± 1.26 |
| 0-6h | 3.66 ± 1.68 | 4.06 ± 1.64 | 3.45 ± 1.82 | 2.86 ± 1.62 | 0.60 ± 1.32 |
| 0-8h | 3.39 ± 1.71 | 3.91 ± 1.69 | 3.22 ± 1.85 | 2.48 ± 1.57 | 0.57 ± 1.31 |
Sum of Pain Intensity Difference (SPID) was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Score range: 0mm = No pain and 100mm = Worst pain. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?'
| units on a scale*hour | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| 0-4h | 1.32 ± 0.73 | 1.46 ± 0.72 | 1.23 ± 0.75 | 1.13 ± 0.70 | 0.18 ± 0.53 |
| 0-6h | 1.32 ± 0.74 | 1.50 ± 0.75 | 1.23 ± 0.76 | 1.01 ± 0.67 | 0.19 ± 0.53 |
| 0-8h | 1.21 ± 0.73 | 1.43 ± 0.75 | 1.14 ± 0.75 | 0.87 ± 0.63 | 0.19 ± 0.53 |
| 0-12h | 0.94 ± 0.64 | 1.18 ± 0.69 | 0.91 ± 0.67 | 0.67 ± 0.57 | 0.19 ± 0.56 |
Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.
| units on a scale*hour | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| 0-4h | 2.33 ± 0.96 | 2.48 ± 0.90 | 2.20 ± 1.04 | 2.05 ± 1.00 | 0.42 ± 0.77 |
| 0-6h | 2.34 ± 1.02 | 2.56 ± 0.98 | 2.22 ± 1.12 | 1.85 ± 1.03 | 0.41 ± 0.82 |
| 0-8h | 2.18 ± 1.05 | 2.48 ± 1.03 | 2.08 ± 1.15 | 1.61 ± 1.01 | 0.38 ± 0.81 |
| 0-12h | 1.73 ± 1.01 | 2.12 ± 1.06 | 1.70 ± 1.11 | 1.27 ± 0.98 | 0.34 ± 0.82 |
SPRID 0-12h: Sum of pain intensity difference (PID) and the pain relief (PR) score over the twelve-hour follow-up period. Score range: 0mm = No pain and 100mm = Worst pain. This was calculated as the area under the curve (AUC) using the method of linear trapezoids assuming that the baseline assessment took place at time zero. Pain intensity (PI) was measured by pain assessment questionnaire, where subject tick the appropriate box in a 4-point ordinal scale ranging from 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain, in response to the question 'What is your pain level at this time?' Total Pain Relief (TOTPAR) was measured using pain assessment diary, where subject tick the appropriate box on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete, in response to the question 'How much relief have you had from your starting pain?'
| units on a scale | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| 15 minutes | 1.12 ± 1.21 | 1.29 ± 1.38 | 0.78 ± 1.22 | 1.01 ± 1.40 | 0.29 ± 0.74 |
| 30 minutes | 2.49 ± 1.63 | 2.79 ± 1.62 | 2.08 ± 1.71 | 2.62 ± 1.83 | 0.58 ± 1.13 |
| 45 minutes | 3.20 ± 1.72 | 3.52 ± 1.64 | 2.92 ± 1.84 | 3.39 ± 1.80 | 0.65 ± 1.38 |
| 60 minutes | 3.71 ± 1.83 | 4.04 ± 1.66 | 3.49 ± 1.98 | 3.81 ± 1.83 | 0.71 ± 1.49 |
| 90 minutes | 4.12 ± 1.82 | 4.44 ± 1.69 | 3.92 ± 2.06 | 3.96 ± 1.77 | 0.60 ± 1.56 |
| 2 hours | 4.28 ± 1.95 | 4.51 ± 1.80 | 4.17 ± 2.14 | 3.91 ± 1.90 | 0.67 ± 1.43 |
| 3 hours | 4.18 ± 2.06 | 4.53 ± 1.95 | 4.02 ± 2.14 | 3.31 ± 2.13 | 1.66 ± 0.00 |
| 4 hours | 4.08 ± 2.09 | 4.46 ± 2.09 | 3.78 ± 2.31 | 2.79 ± 2.21 | 0.64 ± 1.65 |
| 5 hours | 3.77 ± 2.21 | 4.36 ± 2.12 | 3.52 ± 2.40 | 2.23 ± 2.20 | 0.60 ± 1.59 |
| 6 hours | 3.06 ± 2.34 | 3.98 ± 2.24 | 2.98 ± 2.47 | 1.70 ± 2.16 | 0.53 ± 1.56 |
| 7 hours | 2.56 ± 2.37 | 3.51 ± 2.40 | 2.54 ± 2.50 | 1.31 ± 2.00 | 0.45 ± 1.45 |
| 8 hours | 2.09 ± 2.31 | 2.79 ± 2.49 | 2.08 ± 2.38 | 1.02 ± 1.92 | 0.40 ± 1.30 |
| 9 hours | 1.57 ± 2.20 | 2.53 ± 2.47 | 1.68 ± 2.20 | 0.91 ± 1.87 | 0.47 ± 1.59 |
| 10 hours | 1.21 ± 2.02 | 2.04 ± 2.34 | 1.30 ± 2.06 | 0.81 ± 1.84 | 0.49 ± 1.62 |
| 11 hours | 0.90 ± 1.83 | 1.63 ± 2.24 | 1.12 ± 2.02 | 0.76 ± 1.77 | 0.49 ± 1.62 |
| 12 hours | 0.69 ± 1.64 | 1.34 ± 2.14 | 0.96 ± 1.85 | 0.74 ± 1.76 | 0.49 ± 1.62 |
Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.
| units on a scale | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| 15 minutes | 0.40 ± 0.57 | 0.46 ± 0.64 | 0.23 ± 0.58 | 0.31 ± 0.64 | 0.09 ± 0.40 |
| 30 minutes | 0.94 ± 0.76 | 1.03 ± 0.74 | 0.73 ± 0.80 | 0.95 ± 0.83 | 0.15 ± 0.56 |
| 45 minutes | 1.14 ± 0.76 | 1.27 ± 0.76 | 1.04 ± 0.80 | 1.19 ± 0.83 | 0.16 ± 0.63 |
| 60 minutes | 1.31 ± 0.85 | 1.48 ± 0.79 | 1.24 ± 0.87 | 1.35 ± 0.85 | 0.22 ± 0.79 |
| 90 minutes | 1.49 ± 0.83 | 1.61 ± 0.84 | 1.40 ± 0.92 | 1.42 ± 0.83 | 0.11 ± 0.81 |
| 2 hours | 1.54 ± 0.89 | 1.69 ± 0.87 | 1.52 ± 0.94 | 1.41 ± 0.84 | 0.24 ± 0.54 |
| 3 hours | 1.54 ± 0.91 | 1.70 ± 0.89 | 1.46 ± 0.93 | 1.19 ± 0.87 | 0.22 ± 0.66 |
| 4 hours | 1.49 ± 0.91 | 1.68 ± 0.94 | 1.36 ± 0.95 | 0.96 ± 0.90 | 0.24 ± 0.64 |
| 5 hours | 1.35 ± 0.93 | 1.60 ± 0.93 | 1.24 ± 0.96 | 0.79 ± 0.88 | 0.22 ± 0.63 |
| 6 hours | 1.07 ± 0.93 | 1.44 ± 0.93 | 1.04 ± 0.95 | 0.58 ± 0.82 | 0.20 ± 0.62 |
| 7 hours | 0.89 ± 0.93 | 1.22 ± 0.98 | 0.88 ± 0.96 | 0.44 ± 0.74 | 0.18 ± 0.61 |
| 8 hours | 0.71 ± 0.89 | 0.96 ± 0.96 | 0.72 ± 0.89 | 0.33 ± 0.71 | 0.16 ± 0.54 |
| 9 hours | 0.53 ± 0.80 | 0.86 ± 0.94 | 0.55 ± 0.80 | 0.29 ± 0.68 | 0.20 ± 0.68 |
| 10 hours | 0.40 ± 0.74 | 0.67 ± 0.87 | 0.43 ± 0.75 | 0.27 ± 0.67 | 0.20 ± 0.68 |
| 11 hours | 0.27 ± 0.64 | 0.52 ± 0.80 | 0.36 ± 0.73 | 0.24 ± 0.63 | 0.20 ± 0.68 |
| 12 hours | 0.21 ± 0.57 | 0.42 ± 0.78 | 0.30 ± 0.63 | 0.25 ± 0.63 | 0.20 ± 0.68 |
Pain Intensity (PI) VAS was measured using a horizontal 100-mm VAS ranging 0 mm = 'No Pain' as the left anchor and 100 mm = 'Worst Pain' as the right anchor, labelled by the subject marking the VAS line in the pain assessment questionnaire in response to the instruction 'Please indicate with a line on the scale below your pain at this time.'
| units on a scale | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| 15 minutes | 9.0 ± 13.7 | 10.5 ± 16.3 | 4.5 ± 14.1 | 8.7 ± 16.6 | 0.4 ± 13.1 |
| 30 minutes | 22.8 ± 21.4 | 26.2 ± 21.5 | 17.7 ± 22.5 | 23.9 ± 23.9 | 2.2 ± 16.7 |
| 45 minutes | 32.5 ± 23.8 | 37.5 ± 24.0 | 28.3 ± 25.7 | 34.3 ± 25.7 | 0.9 ± 18.8 |
| 60 minutes | 40.3 ± 25.5 | 46.3 ± 24.4 | 36.6 ± 28.7 | 41.5 ± 27.1 | 1.8 ± 19.3 |
| 90 minutes | 48.3 ± 25.8 | 52.5 ± 24.8 | 43.7 ± 28.2 | 44.6 ± 25.9 | 0.9 ± 22.6 |
| 2 hours | 50.6 ± 26.6 | 54.9 ± 25.7 | 47.3 ± 29.3 | 45.2 ± 27.9 | 5.0 ± 18.2 |
| 3 hours | 51.0 ± 27.1 | 55.9 ± 25.5 | 48.0 ± 29.3 | 38.9 ± 29.9 | 6.1 ± 21.3 |
| 4 hours | 50.2 ± 27.8 | 55.5 ± 26.4 | 45.6 ± 29.9 | 32.9 ± 29.4 | 7.2 ± 20.3 |
| 5 hours | 45.4 ± 28.7 | 52.8 ± 26.7 | 42.5 ± 30.4 | 25.9 ± 29.2 | 7.2 ± 19.8 |
| 6 hours | 36.6 ± 30.2 | 47.9 ± 27.8 | 35.6 ± 30.6 | 18.4 ± 27.2 | 6.5 ± 19.7 |
| 7 hours | 30.9 ± 30.6 | 41.0 ± 29.8 | 29.7 ± 30.8 | 15.4 ± 25.2 | 5.8 ± 18.8 |
| 8 hours | 25.0 ± 28.9 | 33.8 ± 30.8 | 24.4 ± 29.8 | 11.7 ± 24.4 | 5.1 ± 17.2 |
| 9 hours | 17.7 ± 26.4 | 29.6 ± 30.3 | 18.4 ± 27.2 | 10.8 ± 22.9 | 5.6 ± 19.4 |
| 10 hours | 14.1 ± 25.2 | 23.7 ± 29.1 | 14.9 ± 25.3 | 9.7 ± 22.9 | 6.2 ± 20.3 |
| 11 hours | 9.4 ± 21.2 | 18.7 ± 27.2 | 12.8 ± 24.7 | 9.8 ± 23.2 | 6.2 ± 20.1 |
| 12 hours | 8.0 ± 20.4 | 15.1 ± 25.5 | 11.0 ± 22.9 | 9.3 ± 22.1 | 6.4 ± 20.8 |
Pain intensity (PI) was measured by pain assessment questionnaire where subject tick the appropriate box in response to the question 'What is your pain level at this time?' PI measured using a 4-point ordinal scale: 0 = No pain, 1 = Mild pain, 2 = Moderate pain, and 3 = Severe pain.
| units on a scale | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Peak Pain Intensity Difference (Peak PID - Ordinal) | 1.78 ± 0.83 | 1.93 ± 0.81 | 1.74 ± 0.87 | 1.63 ± 0.77 | 0.60 ± 0.87 |
Total pain relief (TOTPAR) was measured using pain assessment diary where subject tick the appropriate box in response to the question 'How much relief have you had from your starting pain?' Pain Relief (PR) was rated on a 5-point Ordinal Rating Scale: 0 = None, 1 = A Little, 2 = Some, 3 = A Lot, and 4 = Complete.
| units on a scale | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Peak Pain Relief (PR) | 3.06 ± 1.00 | 3.25 ± 0.89 | 2.98 ± 1.11 | 2.88 ± 1.00 | 0.96 ± 1.15 |
Subject's Overall Assessment measured by subject ticking the appropriate box in response to the question 'How effective do you think the study medication is as a treatment for pain?' Subject's Overall Assessment rated on a five-point ordinal scale: 1 = Poor, 2 = Fair, 3 = Good, 4 = Very good, and 5 = Excellent.
| Participants | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| 1 Poor | 15 | 9 | 15 | 12 | 43 |
| 2 Fair | 16 | 12 | 22 | 19 | 6 |
| 3 Good | 43 | 32 | 40 | 41 | 2 |
| 4 Very good | 72 | 69 | 64 | 34 | 3 |
| 5 Excellent | 23 | 39 | 26 | 7 | 1 |
Collected over Up to Day 10 (follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | 0/173 (0%) | 0/173 (0%) | 88/173 (50.9%) |
| Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | 0/168 (0%) | 0/168 (0%) | 87/168 (51.8%) |
| Nurofen Plus® | 0/169 (0%) | 0/169 (0%) | 97/169 (57.4%) |
| Panadeine® Extra | 0/113 (0%) | 0/113 (0%) | 72/113 (63.7%) |
| Placebo | 0/55 (0%) | 0/55 (0%) | 35/55 (63.6%) |
| Event | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 43/173 | 33/168 | 50/169 | 37/113 | 18/55 |
| VomitingGastrointestinal disorders | 29/173 | 30/168 | 35/169 | 25/113 | 13/55 |
| HeadacheNervous system disorders | 19/173 | 19/168 | 32/169 | 21/113 | 10/55 |
| DizzinessNervous system disorders | 12/173 | 15/168 | 23/169 | 14/113 | 3/55 |
| Alveolar osteitisInfections and infestations | 8/173 | 4/168 | 9/169 | 3/113 | 1/55 |
| Body temperature increasedInvestigations | 2/173 | 3/168 | 9/169 | 3/113 | 1/55 |
| Age, Continuous(years) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 20.2 ± 3.3 | 19.8 ± 3.2 | 20.1 ± 3.4 | 19.7 ± 3.3 | 19.8 ± 3.6 | 20.0 ± 3.3 |
| Sex: Female, Male(Participants) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 105 | 100 | 101 | 68 | 33 | 407 |
| Male | 68 | 68 | 68 | 45 | 22 | 271 |
| Race (NIH/OMB)(Participants) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 2 | 0 | 0 | 3 |
| Asian | 3 | 4 | 7 | 1 | 2 | 17 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 1 | 0 | 3 |
| Black or African American | 4 | 4 | 2 | 3 | 2 | 15 |
| White | 165 | 158 | 154 | 107 | 51 | 635 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 3 | 1 | 0 | 5 |
| Region of Enrollment(participants) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 173 | 168 | 169 | 113 | 55 | 678 |
| Weight(kg) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 68.1 ± 14.5 | 69.0 ± 15.2 | 68.8 ± 15.3 | 70.8 ± 16.1 | 71.0 ± 18.7 | 69.2 ± 15.5 |
| Height(cm) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 168.5 ± 10.0 | 169.3 ± 10.1 | 169.5 ± 9.8 | 168.5 ± 9.7 | 168.7 ± 9.5 | 168.9 ± 9.9 |
| Drink alcohol(participants) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| Number | 63 | 61 | 61 | 36 | 15 | 236 |
| Former smoker(participants) | Ibuprofen 200mg + Paracetamol 500mg (Lower Dose) | Ibuprofen 400mg + Paracetamol 1000mg (Higher Dose) | Nurofen Plus® | Panadeine® Extra | Placebo | Total |
|---|---|---|---|---|---|---|
| Number | 27 | 23 | 20 | 13 | 9 | 92 |
2 further baseline measures are reported on the registry.
The record gives a start of Jan 2009, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 9 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuprofen · Acetaminophen